Drug Database
QL

QL-1209 (QL1209 / QL 1209)

✓ Approved

Qilu Pharmaceutical · ERBB2 · Monoclonal Antibodies

What is QL-1209?

QL-1209 is a monoclonal antibodies developed by Qilu Pharmaceutical. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesQL1209, QL 1209
CompanyQilu Pharmaceutical
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetERBB2
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

QL-1209 acts on 1 molecular target:

ERBB2erb-b2 receptor tyrosine kinase 2 (NEU, CD340)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

QL-1209 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

Related Research Articles

PubMedHealthcare (Basel, Switzerland)2026-08-27

Sex-Specific Determinants of Physical Activity Among Korean Adults Using Weight-Control Medications: A Cross-Sectional Study.

Kim Bo-Young BY

Background/Objectives: The use of weight-control medications (WCMs) has increased rapidly, yet little is known about the physical activity (PA) behaviours of users. Therefore, the present study aimed to identify factors associated with moderate-to-vigorous physical activity (MVPA) among Korean WCM users and to examine sex-specific differences. Methods: This cross-sectional study analysed data from the 2024 Korea Community Health Survey (KCHS). A total of 6604 adults (men: n = 1209; women: n = 5395) using WCMs for weight control were included. Multivariable logistic regression, accounting for complex survey design weights, was conducted separately for men and women. Results: The weighted prevalence of MVPA was higher in men (32.3%) than in women (20.9%). Among men, being unmarried/divorced/widowed (OR = 1.52, 95% CI 1.12-2.07) was positively associated with MVPA, whereas being aged ≥60 years (OR = 0.48, 95% CI 0.28-0.83) was associated with lower odds. Among women, being aged 50-59 years (OR = 1.38, 95% CI 1.07-1.78) was associated with higher MVPA participation, whereas poor self-rated health (OR = 0.60, 95% CI 0.47-0.76) was associated with lower odds. Conclusions: Factors associated with MVPA among WCM users differed between men and women, suggesting that sex-specific approaches may be beneficial when promoting PA in this population. This study is limited by its cross-sectional design and reliance on self-reported data, which preclude causal inference.

PubMedJMIR medical informatics2026-08-21

Patient Stratification for Improving Acute Chest Pain Management and Mitigating Emergency Department Crowding: Machine Learning Model Development and Validation.

Hsieh Chih-Chia CC, Chu Shao-Chung SC, Lee Jung-Ting JT, Lin Chih-Hao CH et al.

Acute chest pain (ACP) is one of the most common chief complaints in the emergency department (ED), accounting for approximately 8% of all ED visits. However, among patients presenting with chest pain suggestive of cardiac origin, fewer than 10% are ultimately diagnosed with acute coronary syndrome (ACS). AI models were developed to support clinical decision-making for triage level-2 ED patients presenting with ACP. These models aim to accurately detect ACS and reliably identify low-risk patients based on a single high-sensitivity cardiac troponin T test result. By integrating this AI-assisted strategy into clinical workflows, we aim to reduce ED length of stay, alleviate crowding, and improve health care efficiency while maintaining high safety standards. We conducted a retrospective study using single-center data from a tertiary teaching hospital between January 2016 and December 2022. Models based on artificial neural networks (ANNs) were trained to classify patients with ACP at triage level 2 into 3 clinical classes: critical patients with ACS (subgroup GA), critical patients without ACS (subgroup GB1), and low-risk patients (subgroup GB2). The models were trained and internally validated via a 5-fold cross-validation protocol using data from 2016 to 2020. Model performance was then evaluated on the hold-out testing data (2021-2022) using area under the receiver operating characteristic curve, area under the precision-recall curve, and subgroup-specific metrics. Feature selection methods and the Shapley Additive Explanations value analysis were applied to identify features that drive the model's predictive power. The study was approved by the institutional review board of the National Cheng Kung University Hospital, Tainan, Taiwan (A-ER-111-199). After excluding ED visits with missing triage data, incomplete medical histories, or unsuitable dispositions, 17,935 visits were included, with 1209 GA, 3873 GB1, and 12,853 GB2. Rendering prediction based on 24 feature variables (2 demographics, 6 vital signs, 4 blood test results, and 12 medical history), all ANN models demonstrated strong testing AUROC (95% CI) performance of 0.942 (0.920-0.965) for GA classification, 0.824 (0.808-0.841) for GB1, and 0.893 (0.884-0.902) for GB2. Regarding multiclassification, ANN-S3 achieved balanced performance, with ACS sensitivity of 0.941 (95% CI 0.908-0.973) and low-risk positive predictive value and sensitivity of 0.911 (95% CI 0.9-0.921) and 0.837 (95% CI 0.824-0.85), respectively. A sensitivity-prioritized variant, ANN-S3-L, increased ACS sensitivity to 0.966 (95% CI 0.94-0.991) and negative predictive value to 0.998 (95% CI 0.996-0.999), but at the cost of lower specificity and reduced low-risk sensitivity, indicating a safety-efficiency trade-off. These findings suggest that ANN-based classifiers can effectively support clinical risk stratification and disposition decision-making in ACP care for patients presenting ≥3 hours after symptom onset. However, because even the sensitivity-prioritized ANN-S3-L variant falls short of the stringent sensitivity threshold (>0.99) typically required for a standalone ED rule-out tool, this system should be interpreted as a clinical decision-support aid rather than an independent rule-out strategy.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-18

Quantum-Like Dynamics in Whole-Brain Models of the Human Connectome.

Deco Gustavo G, Sanz Perl Yonatan Y, Greenstein Natasha N, Chandaria Shamil S et al.

Emerging research provides evidence for quantum-like (QL) probability laws, including interference effects, in non-quantum physical systems using coupled oscillators. In principle, such systems could produce QL states able to support QL computation in biological tissue. In this perspective, we propose a new avenue of research, namely to investigate if this is true in the human brain. Intriguingly, the special topology of human brain anatomy could promote the rich dynamical repertoire in human cognition. As a proof-of-principle, we investigated this by constructing two whole-brain models with and without QL dynamics, where the QL regime is distinguished by a larger whole-brain spectral gap. In accordance with our hypothesis, we found that the QL regime provides a significantly better fit to large-scale human empirical neuroimaging data and exhibits a lower model-derived energy cost than the non-QL model. Furthermore, we constructed a whole-brain model measuring the Växjö Interference term, a measure of functional quantum-like interference showing a significant correlation with the size of the spectral gap. Overall, these results suggest that quantum-like whole-brain models may provide a useful description of large-scale resting-state brain dynamics, and we set out what would be required to test whether this description also carries explanatory value for brain function.

PubMedVaccine2026-08-17

Overestimation of racial ingroup worry about the COVID-19 vaccine and medical racism.

Heiman Samantha L SL, Geiger Nathaniel N

We investigate whether there is pluralistic ignorance-a group-level shared misperception of what other group members are doing, thinking, or feeling-around COVID-19 vaccination and medical racism. We focus on two distinct anti-vaccination movements grounded in distinct racial groups: Black Americans and White Americans. Black American vaccine hesitancy is uniquely grounded in the history and continued reality of medical racism. White American vaccine hesitancy is influenced by factors including social media use, institutional mistrust, and psychological reactance. A Qualtrics panel sample (N = 2425) obtained by recruiting 50% Black (n = 1209) and 50% White (n = 1216) Americans were asked how worried they were regarding medical racism, HIV misinformation, COVID-19 vaccine safety, and whether the COVID-19 vaccine was violating individual rights. They were then asked how worried they felt the average White American and average Black American were on these issues. Black Americans had higher levels of worry on all items than White Americans. Among Black participants, there was a consistent pattern of overestimation of other Black Americans' worry across all issues-both COVID-19 related and medical racism related. Among the White participants, overestimation of group worry was only present for the COVID-19 items, not the items relating to medical racism. For both groups, one's own worry about each outcome and exhibiting Actively Open-Minded Thinking were predictors of overestimations of other's worry.

PubMedCancers2026-08-13

Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms.

Tizro Parastou P, Vail Eric E, Sapkota Manoj M, Gayhart Matthew G MG et al.

Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies characterized by substantial genetic heterogeneity. Although routine molecular evaluation focuses on canonical driver alterations (BCR::ABL1, JAK2, CALR, and MPL), additional somatic mutations have important diagnostic and prognostic implications. We retrospectively analyzed 1209 consecutive patients who underwent peripheral blood next-generation sequencing (NGS) for suspected or established MPNs using a comprehensive 75-gene DNA/RNA panel. Canonical driver alterations were identified in 141 patients, while 1068 were driver-negative. Retrospective analysis demonstrated that 251 patients (21%) harbored at least one additional pathogenic or likely pathogenic mutation that was not routinely reported. Among driver-positive patients, 57 of 141 (40%) carried clinically relevant co-mutations, including high-molecular-risk genes such as ASXL1, TP53, SRSF2, SF3B1, RUNX1, U2AF1, and IDH2. Furthermore, 194 of 1068 (18%) driver-negative patients harbored additional pathogenic mutations, several of which supported clonal hematopoiesis or alternative myeloid neoplasms. Peripheral blood and bone marrow molecular findings demonstrated high concordance (R2 = 0.87). These findings indicate that comprehensive NGS performed at the time of initial evaluation provides clinically relevant genomic information beyond canonical driver mutations, improves disease classification and risk stratification, and may facilitate earlier diagnosis and personalized management of patients with suspected MPNs.

PubMedNutrients2026-08-13

Effects of Beetroot-Derived Nitrate Supplementation in Highly Trained and Elite Athletes: A Scoping Review of Randomized Controlled Trials on Performance, Recovery, and Physiological Outcomes.

Cherappurath Nafih N, Navaf Muhammed M, Yıldız Mevlüt M, Ceylan Halil İbrahim Hİ et al.

Background: Beetroot-derived nitrate supplementation is a widely studied nutritional strategy to enhance athletic performance. Although ergogenic benefits have been reported in recreational and moderately trained individuals, evidence for highly trained and elite athletes remains inconsistent. Objectives: This scoping review aimed to map and synthesize evidence from randomized controlled trials (RCTs) investigating the effects of beetroot-derived nitrate supplementation on performance, recovery, and physiological outcomes in highly trained and elite athletes. Methods: The review followed the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. Literature searches were conducted in PubMed, Scopus, and Web of Science. Eligible studies included RCTs involving McKay Tier 3-5 athletes and evaluating beetroot-derived nitrate supplementation as a standalone intervention. Results: Thirty-one RCTs met the inclusion criteria, representing athletes from a wide range of sports. Supplementation protocols varied substantially, with nitrate doses ranging from 4 to 19.5 mmol·day-1 (248-1209 mg·day-1) and durations from acute administration to 15 days. Positive effects were most frequently reported for cycling time-trial performance, Yo-Yo intermittent recovery performance, anaerobic power, neuromuscular performance, exercise tolerance, and recovery. In contrast, findings for endurance performance, sport-specific skills, oxygen consumption, and perceptual responses were inconsistent despite marked increases in nitrate and nitrite bioavailability. The outcomes seemed to depend on dosage, duration, sport type, and athletes' training status. Conclusions: Beetroot-derived nitrate supplementation may enhance performance in highly trained and elite athletes, particularly during high-intensity and anaerobic activities. However, the effects are inconsistent, underscoring the need for further research to establish optimal supplementation strategies and evaluate long-term efficacy in elite sporting populations.

+3354 more articles available with a free account

Sign up free to view all articles →

Ask about QL-1209